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COX-2 inhibitors Lumiracoxib and Celecoxib, because these
anti-inﬂammatory drugs increase the expression of collagens
types III and IV.
Methods: We evaluated in situ the presence of some
granuloma components such as collagen as well as of its
degradation product hydroxiprline. We also determined the
local presence of relevant cytokines to granuloma formation
and maintainance (TNF-, TGB-,  - IFN, GM-CSF and IL-12)
and also of NO, Pb with preserved or altered morphology and
the overall architecture of the granulomas.
Results: The best indicators of control of PCM as
expressed by successful local Pb lysis were the presence of
compact granulomas, delimited by a continuous deposit of
collagen type 1 arranged in concentric orientation required
to contain the fungi, and the production of high concen-
tration of cytokines IL-12 and -IFN as well as of NO. The
concentration of collagen metabolite per se was not an indi-
cator of Pb containment or dissemination.
Conclusion: Based on these parameters, we can con-
clude that therapy with -IFN and /or Tetracycline seems
promising, reducing the fungal load, increasing the produc-
tion of NO and of the stimulatory cytokines -IFN and IL-12,
decreasing that of the inhibitory cytokine TGB- and altering
the granulomas architecture towards a compact structure in
order to provide Pb containment without excessive ﬁbrosis.
doi:10.1016/j.ijid.2010.02.1756
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Background: Candidiasis is a nosocomial infection associ-
ated to considerable mortality and high economic impact.
The echinocandins are a new class of therapeutic medica-
tions that have shown to be effective in treating candidemia
and other forms of invasive candidiasis; however, cost of
amphotericin B dose is lower. Hypothesis: Is anidulafun-
gin (ANI) costeffective compared to caspofungin (CAS), and
amphotericin B (AMB) in the treatment of invasive candidia-
sis in non-neutropenic patients hospitalized in Intensive Care
Units (ICU) when the ﬂuconazole is not a choice, from a
third-party payer perspective.
Methods: A decision tree was designed to assess the
cost-effectiveness of the three medications and this was
validated by 2 critical care specialists and 2 infectologist.
The model simulated costs and effectiveness in a 14-week-
period. Effectiveness measure was the rate of survival and
the main outcome was saved Life Years (LYs). Clinical efﬁ-
cacy and node probabilities were obtained from a published
meta-analysis that was identiﬁed by systematic literature
review. This study estimated the direct costs associated with
invasive candidiasis treatment including antifungal drugs,
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ospitalization, and costs associated with adverse events.
edical costs were extracted from 7 ICUs of 3 major cities
nd drug costs were taken from a standard colombian cost-
ng source. The incremental cost per successfully treated
atient was calculated and the one way sensitivity analysis
as performed.
Results: Patients treated with ANI experienced the higher
utcomes (13.7 LYs) followed by AMB (12.1 LYs) and CAS (11.7
Ys). Mean cost per patient was lower with AMB (US$4,131)
ollowed by ANI (US$6,001) and CAS (US$6,444). Based on
CERs, ANI was the dominant therapy compared to CAS and
NI was cost-effective compared to AMB (ICER US$1.228).
Conclusion: Anidulafungin represents the cost-effective
reatment of choice when compared to caspofungin and
mphotericin B for the invasive candidiasis in Non-
eutropenic patients in Colombia.
oi:10.1016/j.ijid.2010.02.1757
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Background: Patient presented with ST elevation MI and
ied secondary to multiorgan failure. Autopsy revealed
ngioinvasive aspergillosis involving several organs.
Methods: Case: A 47-year-old African American male with
ast medical history of alcoholinduced cirrhosis presented
ith acute midsternal pain of 5 hours duration. Respiratory
istress developed and mechanical ventilation was required
or airways protection.
Results: Initial work up showed markedly elevated car-
iac enzymes with CPK 14000 U/L, elevated AST 800
/L, ALT 210 U/L, total bilirubin 8mg/dL, direct biliru-
in 7mg/dL, and ST segment elevation on inferior EKG
eads. Patient underwent emergent left heart catheteriza-
ion which revealed patent coronary arteries. Subsequently
ultiorgan failure resulted in decompensated shock and
atient received several vasopressors. Blood, spinal ﬂuid,
rine and sputum cultures showed no growth. Patient had
egative serology for HIV, acute viral hepatitis, syphilis,
engue fever, tularemia, herpes virus 1&2, CMV, EBV,
eptospirosis, Q fever, Lyme disease, brucellosis, and
hrlichiosis. Patient experienced intractable ventricular ﬁb-
illation which resulted in death after a 13-day hospital
tay. Autopsy report conﬁrmed disseminated angioinvasive
spergillosis involving heart, lungs, bowel, thyroid, kidneys
nd spleen in addition to complete occlusion of the poste-
ior descending artery with a fungal thrombus and multiple
ungal vegetations.
Conclusion: Discussion: Aspergillus organisms are ubiq-
itous and exposure to their conidia must be a frequent
vent. However, disease due to tissue invasion is uncommon
nd occurs primarily in the setting of immunosuppression.
isk factors for invasive aspergillosis include prolonged and
evere neutropenia, organ transplantation, AIDS and corti-
osteroid use.
